Pharvaris

PHVS

This company develops oral therapies to treat and prevent hereditary angioedema attacks for patients with rare diseases.

Dyax

This biotechnology firm develops pharmaceutical treatments for hereditary angioedema and other plasma-kallikrein-mediated disorders to assist patients with these rare inflammatory conditions.

Vaderis Therapeutics

This company develops oral AKT inhibitor medicines for patients suffering from hereditary haemorrhagic telangiectasia and other rare vascular diseases.

Third Harmonic Bio

This biopharmaceutical company develops oral small-molecule inhibitors for patients with mast-cell-mediated inflammatory diseases such as chronic urticaria and asthma.

Vicore Pharma

This clinical-stage biopharmaceutical company develops angiotensin II type 2 receptor agonists to treat patients with idiopathic pulmonary fibrosis and other rare lung diseases.

Orvida Pharma (Formerly Kamari)

This biotechnology company develops oral and topical small-molecule treatments for patients with rare and severe genetic skin diseases and chronic itch conditions.

HemaB

Hemab Therapeutics develops prophylactic antibody therapies for patients with rare bleeding and thrombotic disorders including Glanzmann thrombasthenia and Factor VII deficiency.

Areteia Therapeutics

The company develops an oral medication for patients with eosinophilic asthma to reduce inflammation and manage their condition.